CClinicalTrials.gg
CompletedNCT03839082Updated May 3, 2022Results posted

Structured Mobile Technology Based Lifestyle Program vs Usual Care for Patients With Non-alcoholic Fatty Liver Disease

An interventional study of Usual Care then FitBit and FitBit then Usual Care in Non-Alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis, sponsored by University of Michigan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-03.

Sponsored by University of Michigan · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will look at physical activity and nutrition in patients with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH). The researchers will see if providing patients with NAFLD/NASH with specific physical activity and nutrition feedback as an addition to their usual clinical care helps them to lose weight and improve liver-related parameters.

02

Conditions studied

  • Non-Alcoholic Fatty Liver Disease
  • Non-alcoholic Steatohepatitis

Keywords

  • Mobile Technology
  • Weight
  • Nutrition
03

In context

Liver Diseases

2,081 studies on the registry are indexed under Liver Diseases; 390 are open to participants now.

This study's enrollment of 75 is above the median of 50 across 1,323 interventional studies indexed under Liver Diseases.

Browse Liver Diseases studies →

Lead sponsor

University of Michigan is the lead sponsor of 1,475 studies on the registry; 196 are open to participants now.

Of its 162 completed or terminated interventional studies of FDA-regulated products, 128 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH)
  • Access to mobile phone/tablet/ or computer compatible with FitBit application and ability to use said device and application
  • Ability to participate in physical activity

Exclusion criteria

Exclusion Criteria:

  • Any other form of liver disease( Alcohol related liver disease; viral hepatitis, autoimmune liver disease, hereditary forms of liver disease, etc.)
  • History of decompensated cirrhosis
  • Plans for invasive procedures or other regimented lifestyle programs for weight reduction
  • Cardiovascular event in the previous 3 months
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Active comparator
    Usual Care then FitBit

    This is the waitlist control arm.

    Other: Usual Care then FitBit · Other: FitBit then Usual Care

  • Experimental
    FitBit then Usual Care

    Intervention includes education, physical activity, and a nutrition assessment.

    Other: Usual Care then FitBit · Other: FitBit then Usual Care

Interventions

  • OtherUsual Care then FitBit

    Usual care is a visit (15-20 mins) every 6-12 months. Usual care includes a Fibroscan (FDA 510(k) device).

  • OtherFitBit then Usual Care

    Intervention is tailored physical activity and nutritional counseling. Step counts are monitored by a FitBit Zip. A Fibroscan (FDA 510(k) device) is done.

06

What researchers measure

Primary outcomes

  1. Percent Change in Hepatic Steatosis as Measured by Controlled Attenuation Parameter (CAP) Score

    CAP score is generated by a fibroscan. Scores are reported in dB/M ranging from 100-400, with lower scores indicating less hepatic steatosis (Liver fat). Percent change is calculated by (baseline CAP minus follow up CAP) divided by baseline CAP 12 month data, originally planned to assess values after crossover is not presented because no participants completed crossover participation.

    Time frame: Baseline, 6 months,

Secondary outcomes

  1. Percent Change in Body Weight

    Percent change in body weight is measured by (body weight at 6 months minus body weight at baseline) divided by body weight at baseline

    Time frame: Baseline, 6 months

  2. Change in Physical Activity as Measured by International Physical Activity Questionnaire (IPAQ)

    The IPAQ is a validated questionnaire that obtains information on days and minutes per week of different types of physical activity. Scores range from 0 - 500. Score at 6 months minus score at baseline determines change in IPAQ score. A negative change means less physcially active and a positive change means more physically active. Insufficient paired results existed to provide percent change measurements. Medians overall are provided.

    Time frame: Baseline, 6 months

07

Results

Posted May 3, 2022

Participant flow

Initial Randomization
Participant flow — Initial Randomization
MilestoneFitBit Then Usual CareUsual Care Then FitBit
Started3337
Completed712
Not completed2625
Crossover to Other Arm
Participant flow — Crossover to Other Arm
MilestoneFitBit Then Usual CareUsual Care Then FitBit
Started712
Completed00
Not completed712

Outcome measures

PrimaryPercent Change in Hepatic Steatosis as Measured by Controlled Attenuation Parameter (CAP) Score

CAP score is generated by a fibroscan. Scores are reported in dB/M ranging from 100-400, with lower scores indicating less hepatic steatosis (Liver fat). Percent change is calculated by (baseline CAP minus follow up CAP) divided by baseline CAP 12 month data, originally planned to assess values after crossover is not presented because no participants completed crossover participation.

Time frame:
Baseline, 6 months,
Reported as:
Median · percent change
Percent Change in Hepatic Steatosis as Measured by Controlled Attenuation Parameter (CAP) Score
percent changeFitBitUsual Care
Percent Change in Hepatic Steatosis as Measured by Controlled Attenuation Parameter (CAP) Score-13.08.7 (-3.3 to 16.2)
SecondaryPercent Change in Body Weight

Percent change in body weight is measured by (body weight at 6 months minus body weight at baseline) divided by body weight at baseline

Time frame:
Baseline, 6 months
Reported as:
Number · percent change in weight
Percent Change in Body Weight
percent change in weightFitBitUsual Care
Percent Change in Body WeightNA—
SecondaryChange in Physical Activity as Measured by International Physical Activity Questionnaire (IPAQ)

The IPAQ is a validated questionnaire that obtains information on days and minutes per week of different types of physical activity. Scores range from 0 - 500. Score at 6 months minus score at baseline determines change in IPAQ score. A negative change means less physcially active and a positive change means more physically active. Insufficient paired results existed to provide percent change measurements. Medians overall are provided.

Time frame:
Baseline, 6 months
Reported as:
Median · score on a scale
Change in Physical Activity as Measured by International Physical Activity Questionnaire (IPAQ)
score on a scaleFitBitUsual Care
Baseline32.5 (20 to 60)42.5 (30 to 60)
6 months45 (30 to 60)30 (10 to 50)

Adverse events

Collected over While in study - up to 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FitBit0/45 (0%)0/45 (0%)0/45 (0%)
Usual Care0/44 (0%)0/44 (0%)0/44 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)FitBit Then Usual CareUsual Care Then FitBitTotal
Median57 (44 to 65)50 (41 to 61)52.5 (43 to 63)
Sex: Female, Male
Sex: Female, Male(Participants)FitBit Then Usual CareUsual Care Then FitBitTotal
Female211637
Male122133
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FitBit Then Usual CareUsual Care Then FitBitTotal
Hispanic or Latino156
Not Hispanic or Latino322961
Unknown or Not Reported033
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FitBit Then Usual CareUsual Care Then FitBitTotal
Asian134
African-American213
White283058
Other235
Region of Enrollment
Region of Enrollment(participants)FitBit Then Usual CareUsual Care Then FitBitTotal
United States333770
Weight
Weight(pounds)FitBit Then Usual CareUsual Care Then FitBitTotal
Mean204.78 ± 58.62204.40 ± 57.54204.49 ± 57.95
Body Mass Index
Body Mass Index(kg/m^2)FitBit Then Usual CareUsual Care Then FitBitTotal
Median32.4 (28.2 to 38.6)32.02 (28.1 to 36.5)32.2 (28.2 to 37.1)
08

Study locations

1 site
  • The University of Michigan
    Ann Arbor, Michigan 48109, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Nov 12, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03839082
Lead sponsor
University of Michigan
Collaborators
American Association for the Study of Liver Diseases
Responsible party
Monica Tincopa (Clinical Lecturer in Internal Medicine, University of Michigan) — Principal investigator
First posted
Feb 15, 2019
Start date
Mar 20, 2019
Primary completion
Feb 26, 2021
Completion
Feb 26, 2021
Results posted
May 3, 2022
Last update
May 3, 2022

Study contacts

Monica Konerman
principal investigator · University of Michigan

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion